BMO's initiation adds to a bullish consensus backed by insider buying, but the high short interest and downward EPS revisions create a mixed setup. Traders should watch for a catalyst to break the short squeeze potential, but the falling estimates warrant caution on near-term entry.
Price Chart
Executive Summary
BMO Capital initiated coverage on Ascendis Pharma A/S (ASND) at Outperform with a $319 price target, representing 28% upside from the current $248.85. The firm's 53% accuracy on 1,841 calls and 2.3% average return places it near the middle of the 14 firms covering ASND. Consensus is heavily bullish: 25 of 26 analysts rate it Buy, one Hold, zero Sell. The mean price target is $310.30, median $306.45, high $361.21, low $261.39 — BMO's $319 sits above the median and mean, indicating above-consensus conviction. Momentum is positive with one upgrade and zero downgrades in the past 30 days, though EPS estimates for the current quarter and year have been revised down over the past week and month. Insider buying is strong: CEO Jean Jacques Bienaime made two purchases totaling $492,654 on August 14, and other insiders bought in May and June. Short interest is elevated at 68.8% of float, creating potential for a squeeze if positive catalysts materialize. Bottom line: BMO's initiation aligns with a bullish consensus and is reinforced by insider buying, but the high short interest and downward EPS revisions warrant caution.
Impact Score
Consensus & Targets
Consensus is overwhelmingly bullish: 12 Strong Buy, 13 Buy, 1 Hold, 0 Sell, 0 Strong Sell across 26 analysts. That's 96% Buy-equivalent ratings, indicating near-unanimous positive sentiment. BMO's Outperform aligns with this direction.
Current price: $248.85. Mean target: $310.30 (25% upside). Median: $306.45. High: $361.21 (45% upside). Low: $261.39 (5% upside). BMO's $319 is above the mean and median, reflecting above-consensus optimism. The implied upside to BMO's PT is 28%.
Recent Analyst Activity
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-08-19 | BMO Capital | initiate | Outperform | $319.00 |
| 2026-08-14 | TD Cowen | maintain | Buy | $341.00 |
| 2026-08-14 | RBC Capital | maintain | Outperform | $290.00 |
| 2026-08-14 | Barclays | maintain | Overweight | $329.00 |
| 2026-07-23 | Morgan Stanley | maintain | Overweight | $275.00 |
| 2026-07-07 | RBC Capital | maintain | Outperform | $280.00 |
| 2026-05-19 | Citigroup | initiate | Buy | $355.00 |
| 2026-05-15 | Evercore ISI Group | maintain | Outperform | $329.00 |
| 2026-05-11 | Barclays | maintain | Overweight | $345.00 |
| 2026-05-08 | Wells Fargo | maintain | Overweight | $326.00 |
30-day analyst activity: 1 upgrade (BMO's initiation), 0 downgrades. EPS revisions are negative: current quarter EPS estimate fell from $1.32 to $0.95 over 30 days, and current year estimate dropped from $11.82 to $11.34. Next year's estimate also declined from $9.21 to $8.16. This divergence — bullish ratings but falling estimates — is a cautionary signal.
Firm Track Record — BMO Capital
BMO Capital accuracy: 53% on 1841 calls | avg return: 2.3%
Industry benchmark: mean 51% ± 11%. Top tier: ≥61% (mean + 1σ). Based on 14 firms with ≥5 scored calls.
| Firm | Accuracy | Calls | Avg Return | vs Average |
|---|---|---|---|---|
| RBC Capital | 100% | 3/3 | 5.2% | top tier |
| Wedbush | 100% | 4/4 | 5.8% | top tier |
| UBS | 100% | 2/2 | 2.7% | top tier |
| TD Cowen | 100% | 4/4 | 8.3% | top tier |
| Stifel | 100% | 4/4 | 7% | top tier |
| B of A Securities | 80% | 4/5 | 7.7% | top tier |
| Oppenheimer | 80% | 4/5 | 7.3% | top tier |
| Citigroup | 75% | 3/4 | 7.4% | top tier |
| Evercore ISI Group | 67% | 2/3 | -0.7% | top tier |
| Morgan Stanley | 67% | 2/3 | 6.1% | top tier |
BMO Capital has a 53% accuracy rate on 1,841 calls with a 2.3% average return, placing it in the middle of the pack. Top-tier firms covering ASND include RBC Capital (100% on 3 calls, 5.2% avg return), Wedbush (100% on 4, 5.8%), TD Cowen (100% on 4, 8.3%), and Stifel (100% on 4, 7.0%). Bottom-tier: Goldman Sachs (33% on 3, -0.2%) and Wells Fargo (50% on 4, 1.3%). BMO's initiation is not from a top-tier firm but is still credible.
Earnings Estimates
| Period | EPS Est. | EPS Range | Revenue | Revisions (7d) |
|---|---|---|---|---|
| 0q | $0.95 | $0.68 — $1.09 | $365.8M | ↑0 ↓0 |
| 0y | $11.34 | $3.61 — $15.60 | $1.4B | ↑1 ↓0 |
| +1y | $8.16 | $6.64 — $8.78 | $2.0B | ↑1 ↓0 |
| +1q | $1.18 | $0.67 — $1.51 | $415.1M | ↑0 ↓0 |
Cross-Platform Signals
Insider trades are strongly bullish: CEO Jean Jacques Bienaime bought $492,654 worth on August 14, and other insiders (Scott Thomas Smith, Bienaime) made buys in May/June totaling ~$88,710. No insider sales reported. Institutional activity is mixed: State Street doubled its position (+488.5% to $137M), but BlackRock, Deutsche Bank, National Bank of Canada, and TD Asset Management all exited. Short interest is high at 68.8% of float, suggesting significant bearish positioning. The insider buying aligns with the bullish analyst signal, while the short interest creates potential for a squeeze if positive news hits.
Investment Themes
Documents Analyzed
Report based on filing metadata.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 23d ago | Insider Cluster | $260.81 $247.69 | ▼ −5.03% | ▼ −4.37% | $227.23 (−12.88%) |
Aug 31, 2026 4w ago | 6-K | $260.25 $260.81 | ▲ +0.22% | ▲ +0.13% | $227.23 (−12.69%) |
Aug 27, 2026 5w ago | ANALYST-UPGRADE | $249.36 $271.12 | ▲ +8.73% | ▲ +8.46% | $227.23 (−8.87%) |
Aug 19, 2026 6w ago | ANALYST-UPGRADE | $259.62 $250.25 | ▼ −3.61% | ▼ −3.22% | $227.23 (−12.48%) |
Aug 19, 2026 6w ago | Insider Buy | $259.62 $250.25 | ▼ −3.61% | ▼ −3.22% | $227.23 (−12.48%) |
Aug 13, 2026 7w ago | 6-K | $246.23 $254.81 | ▲ +3.48% | ▲ +5.45% | $227.23 (−7.72%) |
Aug 13, 2026 7w ago | Press Release | $246.23 $254.81 | ▲ +3.48% | ▲ +5.45% | $227.23 (−7.72%) |
Aug 6, 2026 8w ago | 6-K | $249.85 $246.23 | ▼ −1.45% | ▼ −2.66% | $227.23 (−9.05%) |
Aug 6, 2026 8w ago | Press Release | $249.85 $246.23 | ▼ −1.45% | ▼ −2.66% | $227.23 (−9.05%) |
Jul 15, 2026 11w ago | 6-K | $259.80 $252.66 | ▼ −2.75% | ▼ −1.08% | $227.23 (−12.54%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access